Get the latest news on immunotherapy

September 1, 2023

TACTI-002 data show antitumor activity with second-line Eftilagimod Alpha and PD-1 inhibition in HNSCC

August 30, 2023

Unlocking tumor immune evasion: IL1RL1+ Treg cells and CAFs collaborate for immunotherapy resistance

August 30, 2023

New discoveries about a type of immune cells could pave the way for improved immunotherapies

August 25, 2023

mRNA immunotherapy targets cancer

August 24, 2023

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

August 23, 2023

Combination immunotherapy effective for second-line melanoma treatment

August 23, 2023

Pembrolizumab outperforms ipilimumab in 7-year follow-up of patients with advanced melanoma

August 23, 2023

1st ARPA-H Grant: mRNA-based anti-cancer and anti-microbial vaccine development

August 22, 2023

Adjuvant Nivolumab approved in Europe for completely resected stage IIB or IIC melanoma

August 17, 2023

Immunotherapy combo could overcome melanoma anti-PD-1 resistance

August 15, 2023

Addition of navitoclax to dabrafenib/trametinib aims to improve efficacy of targeted therapy in BRAF+ Metastatic Melanoma

August 15, 2023

FDA issues final guidance on obtaining informed consent in drug and device clinical trials

August 9, 2023

Deep-learning technology could help scientists to develop personalized immunotherapies and vaccines

August 9, 2023

Chronic immune-related adverse effects common in patients with resected melanoma treated with Anti-PD-1 therapy

August 8, 2023

Immunotherapy may lead to chronic side effects

August 7, 2023

As new immunotherapy resistance definitions take shape, adoption challenges remain

August 2, 2023

Bispecific Antibodies: an area of research and clinical applications

July 31, 2023

Newly identified protein plays a key role in the action of emerging anticancer therapies

July 27, 2023

Yale scientists identify immune cells critical for immunologic memory for melanoma

July 26, 2023

Bispecific antibodies reach the clinic, with more advances ahead

July 26, 2023

Atezolizumab, Vemurafenib, and Cobimetinib in patients with BRAF V600–Mutated Melanoma and CNS Metastases

July 26, 2023

Tumor-derived GDF-15 suppresses immunotherapy response

July 26, 2023

Merck and Moderna initiate phase 3 study evaluating V940 (mRNA-4157) in combination with KEYTRUDA® (pembrolizumab) for adjuvant treatment of patients with resected high-risk(Stage IIB-IV) melanoma

July 24, 2023

3D Bioprinting could make cancer treatment more effective

July 21, 2023

Immunotherapy insights: oncolytic viruses struggle to find a spot in a crowded field

July 21, 2023

First-line immunotherapy Is associated with worse survival outcomes in synchronous mRCC

July 21, 2023

Immunotherapy Insights: Oncolytic viruses struggle to find a spot in a crowded field

July 21, 2023

Advances in cancer immunotherapy: breakthrough techniques and key players explored in new report

July 7, 2023

Melanoma: targeting protein may help boost skin cancer immunotherapy

June 30, 2023

Adjuvant Pembrolizumab continues to provide survival benefit in Stage IIB/C Melanoma

June 29, 2023

ASCO 2023: continued success with immunotherapy in melanoma

June 28, 2023

Evaluating the efficacy of Neoadjuvant checkpoint immunotherapy in melanoma treatment

June 26, 2023

Spotlight on immunotherapy at ASCO23

June 25, 2023

Camrelizumab plus Famitinib demonstrates early antitumor activity in advanced melanoma

June 23, 2023

Treatment-Free survival after Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for advanced melanoma

June 23, 2023

Opdivo, Opdualag still benefits patients with melanoma at 2 years

June 21, 2023

Study hints at how cancer immunotherapy can be safer

June 12, 2023

First-Line, Fixed-Duration Nivolumab plus Ipilimumab followed by Nivolumab in clinically diverse patient populations with unresectable Stage III or IV Melanoma: CheckMate 401

June 6, 2023

ASCO 2023: Moderna and MSD’s vaccine/IO combo reduces chances of melanoma spreading

June 6, 2023

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

June 3, 2023

Is Pembrolizumab effective in patients with brain metastases?

June 3, 2023

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

May 31, 2023

Relatlimab/Nivolumab shows clinical activity in patients with heavily pretreated advanced melanoma

May 30, 2023

Single-cell RNA sequencing data reveals T cells linked to cancer immunotherapy resistance

May 28, 2023

STING like a bee: MIT’s revolutionary approach to cancer immunotherapy

May 26, 2023

Podcast: ASCO23: RELATIVITY-047, CheckMate-038, and other advances in immunotherapy

May 23, 2023

Tumor mutational burden and outcomes in patients with advanced cancers treated with Immune Checkpoint Inhibitors

May 17, 2023

New computational tool identifies novel targets for cancer immunotherapy

May 16, 2023

CT researchers: Vaccine to fight cancer shows promise using same mRNA technology as COVID drug

May 12, 2023

Putting the STING into cancer immunotherapy

May 11, 2023

New Immunotherapy approach reverses T Cell exhaustion

May 8, 2023

Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment

May 3, 2023

Immunotherapy in the fight against solid tumors

May 3, 2023

Immunotherapy for cancer: a look back and a look ahead

April 30, 2023

Rationale for immunotherapy in melanoma regardless of BRAF status

April 28, 2023

Neoadjuvant checkpoint immunotherapy and melanoma: the time is now

April 26, 2023

How mutant protein leads to melanoma

April 25, 2023

New class of immunotherapy shows promise against aggressive skin cancer

April 22, 2023

mRNA vaccine plus pembrolizumab, minimizes recurrence rate in melanoma

April 19, 2023

AACR meeting 2023: mRNA-4157 vaccine from Moderna shows promise in high-risk melanoma

April 18, 2023

Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival

April 16, 2023

Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return

April 11, 2023

Tavokinogene/pembrolizumab yields responses but misses end point in melanoma

April 8, 2023

Cancer treatment’s checkpoint inhibitors are causing skin-related adverse events

April 6, 2023

Study reveals how diet and probiotics boost melanoma immunotherapy response

April 5, 2023

The future of immunotherapy targets

April 2, 2023

Treatment of solid tumor malignancies is improving but still toxic, requires critical evaluation by oncology pharmacist

March 30, 2023

A new generation of cytokine-based Immunotherapy takes shape

March 30, 2023

EC approves Regeneron’s Libtayo along with chemotherapy for NSCLC

March 30, 2023

Merck nabs full FDA approval for Keytruda in MSI-High, dMMR Solid Tumors

March 22, 2023

Immunotherapy against solid tumors may be more effective with intact lymph nodes

March 18, 2023

Cancer treatment’s checkpoint inhibitors are causing skin-related side effects

March 16, 2023

Earlier appears better for immunotherapy in melanoma

March 15, 2023

Study offers a potential strategy to improve T Cell therapy in solid tumors

March 9, 2023

Innovation in immuno-oncology: Leading companies in in-vitro T-cell activation

March 8, 2023

FDA agrees to review Opdivo for post-surgical melanoma treatment

March 5, 2023

Consistent durable responses are observed for Lifileucel in Melanoma regardless of IL-2 doses

March 5, 2023

Nivolumab may yield more IRAEs in those with cancer who have a higher BMI

March 2, 2023

Immunotherapy before surgery significantly improves outcomes of patients with melanoma

February 28, 2023

FDA accepts sBLA of nivolumab monotherapy for Stage IIB/IIC Melanoma

February 28, 2023

U.S. Food and Drug Administration accepts Bristol Myers Squibb’s supplemental biologics license application and European Medicines Agency validates application for Opdivo (nivolumab) ….

February 22, 2023

Immunotherapy response affected by CD5+ cells

February 21, 2023

Nivolumab and relatlimab in patients with advanced melanoma progressing on Anti–PD-1/PD-L1 Therapy

February 16, 2023

Cancer patients who don’t respond to immunotherapy lack crucial immune cells

February 13, 2023

Nivolumab and Relatlimab in patients with advanced melanoma that had progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: results from the Phase I/IIa RELATIVITY-020 Trial

February 10, 2023

CAR-T cell cancer immunotherapy gets personal

February 8, 2023

Oncolytic virus/immunotherapy combination delivers early survival benefit in melanoma

February 6, 2023

A data-informed Approach to first-line treatment selection

February 3, 2023

Molecular anchor creates more effective CAR T Immunotherapies

February 1, 2023

Neoadjuvant Therapy Helps Shape Changing Landscape of Early-Stage NSCLC

January 31, 2023

Brentuximab Vedotin Plus Nivolumab/Dacarbazine/Doxorubicin Produces Promising Efficacy in Hodgkin Lymphoma

January 26, 2023

Study identifies the DNA roots of resistance to targeted cancer therapy

January 26, 2023

‘Persistent’ subset of tumor mutations may predict immunotherapy response

January 23, 2023

Dietary plant sugar promotes antitumor immunity and enhances the efficacy of immunotherapy

January 12, 2023

Calcium signaling induced by 15-deoxy-prostamide-J2 shown to promote cell death

January 11, 2023

Cytokine-labelled T Cells boost cancer Immunotherapies

January 10, 2023

Could PD-L1/2 structural variants be the next pan-cancer predictive immunotherapy biomarker?

January 10, 2023

Low-Dose Nivolumab plus chemotherapy an accessible alternative to full-dose checkpoint inhibitors in head and neck cancers

January 10, 2023

A platform-agnostic approach to building a diversified Immuno-Oncology portfolio

January 8, 2023

Neoadjuvant SHR-1701 Increases Response, Resectability in Stage III Unresectable NSCLC

December 23, 2022

RP1 plus Nivolumab generates activity in pretreated cutaneous melanoma

December 23, 2022

Emergence of Tebentafusp underscores the need for additional advancements in uveal melanoma

December 23, 2022

Immunotherapy may be improved by extracellular vesicles

December 20, 2022

Data sharing from cancer drug trials falls short of promises, study authors say

December 20, 2022

Moderna’s oncology aspirations grow with mRNA vaccine success in melanoma

December 19, 2022

Immunotherapy makes major strides for first-line treatment of unresectable locally advanced or metastatic esophageal squamous cell carcinoma

December 16, 2022

Risk of side effects from cancer immunotherapy linked to genetics

December 15, 2022

PD-L1 status could help inform patient selection for IO-based therapy in HNSCC

December 8, 2022

Instil Bio announces prioritization of genetically engineered CoStAR-TIL Program with ITIL-306 in advanced solid tumors and reduction in workforce

December 6, 2022

Whole body scan shows the complexity of the immunotherapy response

December 4, 2022

A Yale University study presents a new explanation for why immunotherapy only works for some cancer patients.

November 28, 2022

Biomarkers found for hyper-progression of melanoma after Immunotherapy

November 23, 2022

Novel ‘prodrug’ designed to eliminate cancer without harming healthy cells

November 21, 2022

Nanotechnology platform sensitizes cancer cells to immunotherapy

November 21, 2022

New published study further demonstrates the ability of Natera’s mPCR technology to monitor immunotherapy response in metastatic uveal melanoma patients

November 16, 2022

Tumor infiltrating lymphocyte data signal promise for new options to treat advanced melanoma

November 16, 2022

First-In-Class Immune Checkpoint Therapy unlocks NK cell attack on tumors

November 16, 2022

Sotigalimab/Pembrolizumab combo continues to show clinical activity in frontline melanoma

November 16, 2022

Promising new cancer immunotherapy developed

November 13, 2022

Evolving immunotherapy data shed light on best practices in metastatic melanoma

November 10, 2022

US FDA approves Regeneron Pharma’s Libtayo in combination with chemotherapy as first-line treatment for advanced NSCLC

November 8, 2022

DREAM seq trial clarifies treatment sequencing in BRAF V600–Mutant Melanoma

November 7, 2022

Iovance Biotherapeutics anounces updated clinical data for Lifileucel in advanced melanoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 28, 2022

Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma

October 27, 2022

Why immunotherapy works well for some cancer patients, but not others

October 25, 2022

Are NK-Cell–Based treatments the next approach in Immuno-Oncology?

October 23, 2022

Treating skin cancers in the immunotherap era

October 21, 2022

Immunotherapy and BRAF-Targeted therapy fill expanded roles across melanoma

October 19, 2022

Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma

October 18, 2022

Tebentafusp-tebn use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal Melanoma

October 17, 2022

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

October 14, 2022

Cancer “vaccines” enter the neoantigen stage

October 8, 2022

Immunotherapy in SCC still marred by challenges, despite efficacy in some patients

October 6, 2022

BLA submitted to the FDA for Denileukin Diftitox in cutaneous persistent/recurrent T-Cell Lymphoma

October 6, 2022

Adjuvant Nivolumab/Ipilimumab vs Nivolumab in resected stage IIIB–D or IV Melanoma

October 5, 2022

Yervoy-Opdivo combination may not improve outcomes versus Opdivo alone for some patients with high-risk Melanoma

September 28, 2022

Increased melanoma survival with immunotherapy followed by targeted therapy (DreamSeq)

September 26, 2022

Induction exposure dose of Ipilimumab and failure of adjuvant Nivolumab plus Ipilimumab in melanoma

September 22, 2022

Cleveland Clinic’s ROBIN center may pave way for more effective radiation, immunotherapy treatments

September 19, 2022

Adjuvant Nivolumab yields meaningful improvement in RFS vs placebo in Stage IIB/C Melanoma

September 16, 2022

Bristol Myers Squibb receives European Commission approval for LAG-3-blocking antibody combination, Opdualag (nivolumab and relatlimab), for the treatment of unresectable or metastatic mMelanoma with tumor cell PD-L1 Expression < 1%

September 15, 2022

Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial

September 15, 2022

Bristol Myers Squibb announces adjuvant treatment with Opdivo (nivolumab) demonstrated statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) in patients with Stage IIB/C Melanoma in the CheckMate -76K trial

September 14, 2022

Regeneron, Immutep talk LAG-3 as ESMO highlights new I-O approaches

September 12, 2022

Positive neoadjuvant Libtayo® (Cemiplimab) monotherapy data in resectable cutaneous squamous cell carcinoma presented at ESMO and published in NEJM

September 12, 2022

Fianlimab (LAG-3 Inhibitor) combined with Libtayo® (CemiIpliImab) demonstrates greater than 60% response rates in two independent cohorts of patients with advanced melanoma naïve to PD-1 or PD-L1 Inhibitors

September 12, 2022

Immunotherapy before surgery boosts survival in skin cancer

September 11, 2022

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

September 9, 2022

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response

September 6, 2022

Metabolic enzyme inhibition kills melanoma cells, stops tumor growth

September 6, 2022

More Effective Cancer Immunotherapy: Stanford’s New Method To Find Antigens That Trigger Specific Immune Cells

September 2, 2022

Keytruda Plus T-VEC falls short in unresectable melanoma

August 31, 2022

Five ways to measure immunotherapy potency

August 31, 2022

Oncolytic Virotherapy combined with immunotherapy shows promise against resistant cancers

August 26, 2022

Some cancer immunotherapy treatments may damage fertility

August 25, 2022

CRISPR engineers stronger T Cells for immunotherapy

August 16, 2022

mRNA-Based Cancer Vaccine Effectively Targets Tumors in Mice

August 10, 2022

Israeli scientists racing to deliver world’s 1st pill-form immunotherapy for cancer

August 8, 2022

Immuno-Genomic features predict treatment response in esophageal carcinoma

August 6, 2022

Nivolumab in combination with chemotherapy or ipilimumab prolongs life in comparison with chemotherapy alone

August 1, 2022

How has immunotherapy improved survival rates in patients with melanoma?

July 27, 2022

LAG-3 fills a complex role in the immune system

July 26, 2022

Examining emerging targets within cancer immunotherapy

July 25, 2022

Immune checkpoint inhibitors at ASCO: long-term efficacy data mount

July 25, 2022

Mode-of-action of T-cell immunotherapies in focus

July 20, 2022

Bristol Myers Squibb receives positive CHMP opinion recommending approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for treatment of patients with unresectable or metastatic melanoma

July 20, 2022

Keytruda treatment regimen misses survival goal in head and neck cancer

July 14, 2022

Evan Lipson, MD, on nivolumab plus relatlimab for advanced melanoma

July 13, 2022

POLE/POLD1 mutations in cancer improve immunotherapy response

July 11, 2022

Immune activation may ‘Hinge’ on antibody flexibility

July 8, 2022

Acetaminophen blunts antitumor activity of immunotherapy

July 8, 2022

Whole exome sequencing predicts whether patients respond to cancer immunotherapy

June 24, 2022

Facts and hopes for gut microbiota interventions in cancer immunotherapy

June 24, 2022

Cobolimab plus Dostarlimab achieves clinical responses in advanced melanoma

June 19, 2022

10 Years of Immunotherapy: advances, innovations, and better patient outcomes

June 16, 2022

Cosibelimab continues to show promise in locally advanced cutaneous squamous cell carcinoma

June 15, 2022

Learning to beat the clock—stressing the timing of immunotherapy

June 13, 2022

FDA approves new oncology therapies faster than EMA, study finds

June 13, 2022

Using immunotherapy to prevent cancer metastases

June 10, 2022

Immunotherapy may get a boost

June 7, 2022

Mario Sznol, MD, and Stefania Scala, MD, on Improving Responses to Immunotherapy in Patients With Melanoma

June 7, 2022

Georgina V. Long, MD, PhD, on Melanoma: new data on pembrolizumab, dabrafenib, and trametinib

June 7, 2022

Georgina V. Long, MD, PhD, on Melanoma: distant metastasis–free survival with adjuvant pembrolizumab

June 7, 2022

PDS0101 shows synergistic activity with pembrolizumab in HPV16+ head and neck squamous cell carcinoma

June 7, 2022

War against NRAS-mutant melanoma using targeted therapies remains challenging

June 7, 2022

Concurrent therapy improves responses, increases toxicity in stage III melanoma

June 6, 2022

Nivolumab plus relatlimab demonstrates sustained PFS benefit in advanced melanoma

June 1, 2022

Opdivo-based regimens approved as first-line treatments for esophageal cancer

May 31, 2022

Neoadjuvant immunotherapy for advanced, resectable CSCC-HN

May 27, 2022

Desmoplastic melanoma responds to PD-1 blockade immunotherapy

May 26, 2022

Z-DNA triggering drug kills immunotherapy resistant melanoma by mimicking flu

May 25, 2022

Approaches to Potentiate Immune Response in patients who do not respond to Anti–PD-1 therapy for melanoma

May 24, 2022

Immunotherapy trial gives melanoma patient a chance for recovery without surgery

May 20, 2022

Merck receives positive EU CHMP opinion for KEYTRUDA® (pembrolizumab) as adjuvant treatment for adult and adolescent (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection

May 18, 2022

BIO Biotech announces initiation of phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma

May 16, 2022

Immunotherapy offers hopeful outcomes in nonmelanoma skin cancers

May 13, 2022

Sotigalimab plus nivolumab shows encouraging activity in Anti–PD-1 refractory melanoma

May 10, 2022

T-Cell behavior influences which tumors respond to immunotherapy

May 9, 2022

Targeting interleukin-6 could help relieve immunotherapy side effects

May 5, 2022

Failed clinical trial leads to scientific breakthrough: investigating cancer drug toxicity leads to critical discovery

May 3, 2022

Hot topic: a prognostic liquid biopsy for use with uveal melanoma is predictive of metastasis

April 26, 2022

Administration of RP1 through intratumoral injection offers unique advantages in melanoma treatment

April 25, 2022

RELATIVITY-047 update: novel immunotherapy duo delays disease progression in advanced melanoma

April 24, 2022

Soluble microenvironment appears to impact how melanoma cells interact with immune cells

April 23, 2022

Sotigalimab/Pembrolizumab jumpstarts immune activity, ignites clinical responses in metastatic melanoma

April 22, 2022

Some reassurance on neurologic effects of checkpoint inhibitors

April 20, 2022

SKI scientists identify potential new ‘soldier’ for cancer immunotherapy

April 15, 2022

Tumor-directed oncolytic immunotherapies show promise in Replimune clinical update

April 13, 2022

Researchers load CAR T cells with oncolytic virus to treat solid cancer tumors

April 8, 2022

Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma

March 30, 2022

Replimune provides new clinical data, broad program update and future development strategy for its tumor-directed oncolytic immunotherapies

March 30, 2022

Novel CTLA-4 agents build on immunotherapy foundation, aim to improve efficacy/safety

March 28, 2022

Monitoring, managing immunotherapy and immune-related adverse events

March 28, 2022

Implantable immunotherapy “factory” fights cancer faster, more effectively

March 22, 2022

Enzyme revealed as promising new target for cancer immunotherapies

March 18, 2022

Bristol Myers’ Opdivo combo Opdualag scores FDA approval in melanoma, opens 3rd immune checkpoint drug class

March 17, 2022

Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC) | BioSpace

March 15, 2022

Merck announces KEYLYNK-010 trial evaluating KEYTRUDA® (pembrolizumab) in combination with LYNPARZA® (olaparib) in patients with metastatic Castration-resistant prostate cancer to stop for futility

March 15, 2022

Relatlimab/Nivolumab Combo Continues to Impress in Previously Untreated Metastatic or Unresectable Melanoma

March 15, 2022

Plasmid DNA vaccine candidate’s phase 1 study targets rare but aggressive form of skin cancer

March 14, 2022

Bristol Myers Squibb and Nektar announce update on phase 3 PIVOT IO-001 trial evaluating Bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma

March 13, 2022

Researchers uncover immune environment of rare type of melanoma

March 11, 2022

New research seeks to incorporate immunotherapy into early lines of ESCC treatment

March 3, 2022

Genome and Company announces Clinical Trial Collaboration with MSD to evaluate ‘GEN-001’ in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients

February 22, 2022

BioNTech and Medigene link up for solid tumor T-Cell treatments

February 20, 2022

The value of a high-fiber diet for melanoma patients on immunotherapy

February 18, 2022

Applied DNA and EvviVax publish data for potential cancer immunotherapy

February 18, 2022

Long-term follow-up data reinforce continued overall survival benefit of BAVENCIO® (avelumab) first-line maintenance treatment in patients with advanced urothelial carcinoma

February 17, 2022

Study finds early signs of response to immunotherapy for melanoma in blood

February 17, 2022

Vitiligo from checkpoint inhibitors not limited to melanoma

February 16, 2022

Progress in study combining PD-1 inhibitor pembrolizumab and anti-inflammatory drug vilobelimab in squamous cell skin cancer

February 15, 2022

Combination cancer immunotherapy with dendritic cell vaccine and nanoparticles loaded with interleukin-15 and anti-beta-catenin siRNA significantly inhibits cancer growth and induces anti-tumor immune response

February 15, 2022

Potential use of FDG-PET findings in reducing duration of immunotherapy in patients with advanced melanoma

February 15, 2022

Prognostic impact of baseline neutrophil-to-eosinophil ratio in patients with metastatic renal cell carcinoma treated with nivolumab therapy in second or later lines

February 15, 2022

Early studies investigate novel vaccine strategy in Merkel cell carcinoma

February 14, 2022

Avalon GloboCare expands its cellular immuno-oncology platform with the addition of novel chimeric antigen receptor-natural killer (CAR-NK) cell therapies

February 14, 2022

Newly approved tebentafusp requires up-front active toxicity management in melanoma

February 14, 2022

Differentiating pseudoprogression from hyperprogression in patients treated with immunotherapies

February 14, 2022

Report finds cancer immunotherapy clinical trials to grow globally

February 8, 2022

Frontline selinexor maintenance improves PFS in advanced or recurrent endometrial cancer

February 7, 2022

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma

February 7, 2022

Immunomic Therapeutics announces clinical trial of ITI-3000 for the treatment of merkel cell carcinoma

February 3, 2022

Dr. Ramalingam on the results of an exploratory analysis of the CheckMate 227 trial in NSCLC

January 31, 2022

Pembrolizumab shows durable activity in subset of women with endometrial cancer

January 31, 2022

Novel first-line melanoma therapy could be limited to a niche patient subgroup

January 30, 2022

Eisai: Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) approved in Taiwan for the first-line treatment of patients with advanced renal cell carcinoma

January 29, 2022

Patients with treatment-naïve RCC achieve superior quality of life with nivolumab/cabozantinib

January 28, 2022

Regeneron and Sanofi provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer

January 28, 2022

Expert explains significance of LAG-3 inhibition in novel immunotherapies for melanoma

January 27, 2022

Merck’s Keytruda obtains European Commission approval as adjuvant therapy for kidney cancer

January 26, 2022

Longer follow-up shows improved disease-free survival with nivolumab in patients with high-risk muscle-invasive urothelial carcinoma (MIUC)

January 26, 2022

Selecting treatment options for relapsed/refractory multiple myeloma

January 26, 2022

FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma

January 26, 2022

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology

January 26, 2022

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

January 25, 2022

OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi® after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients

January 24, 2022

First-in-human trial with CAR macrophages shows promise targeting solid tumors

January 22, 2022

Updated CheckMate 649 results show sustain benefit of nivolumab plus chemo for gastric/GEJ cancer

January 20, 2022

Results from pivotal phase 3 KEYNOTE-775/Study 309 trial of KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) in advanced endometrial carcinoma published in the New England Journal of Medicine

January 19, 2022

23andMe details genetically informed cancer immunotherapy development plans

January 18, 2022

Evaxion Biotech receives regulatory clearance to initiate phase 2 trial of EVX-01 in combination with KEYTRUDA® for treatment of melanoma

January 16, 2022

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

January 14, 2022

Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: Real-world data assessment

January 13, 2022

A lower dose of Xpovio (selinexor) may help patients with myeloma get the ‘full benefit of the drug’

January 13, 2022

Nivolumab achieves durable responses and extends OS versus sorafenib in HCC

January 13, 2022

Adagene : Announces first patients with advanced non-small cell lung cancer dosed in phase 1b/2 clinical trial of ADG106 in combination with nivolumab in Singapore

January 12, 2022

Biomica announces clearance for first-in-human phase I study of BMC-128 in combination with Bristol Myers Squibb’s anti-PD-1 Opdivo®

January 12, 2022

IMV announces first patient dosed in the VITALIZE Phase 2B clinical study evaluating its lead compound, MVP-S, in combination with KEYTRUDA® (pembrolizumab) in patients with relapsed/refractory diffuse large B cell lymphoma

January 11, 2022

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

January 11, 2022

Study: Relatlimab, nivolumab improve progression-free survival in metastatic melanoma

January 10, 2022

BioAtla announces clinical collaboration with Bristol Myers Squibb to study mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) in combination with Opdivo® (nivolumab) for treatment of solid tumors

January 7, 2022

Merck’s Keytruda scores key NICE sign-off for first-line NSCLC indication

January 6, 2022

23andMe initiates phase 1 clinical trial for first wholly-owned immuno-oncology antibody for patients with solid tumors

January 6, 2022

Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma

January 4, 2022

Inhibrx announces initial phase 1 dose escalation results for INBRX-106, a novel hexavalent OX40 agonist, in combination with Keytruda® (pembrolizumab) for NSCLC and melanoma patients

January 4, 2022

Vaccinex reports phase Ib KEYNOTE B84 combination study of Keytruda® and pepinemab in patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) passes planned interim safety analysis

January 4, 2022

Vaccinex reports phase Ib KEYNOTE B84 combination study of Keytruda® and pepinemab in patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) passes planned interim safety analysis

January 3, 2022

Genprex receives FDA Fast Track Designation For REQORSA – Keytruda for NSCLC treatment

January 3, 2022

Nivolumab plus ipilimumab linked to treatment-free survival boost in kidney cancer

January 3, 2022

First-line nivolumab/ipilimumab yields durable survival benefit in asymptomatic melanoma with brain mets

January 3, 2022

Genprex wins Fast Track designation for REQORSA in combo with Keytruda for treating non-small cell lung cancer from FDA

December 31, 2021

Etigilimab/nivolumab combo yields promising efficacy and safety in metastatic solid tumors

December 29, 2021

FDA approval sought for teclistamab for relapsed/refractory multiple myeloma

December 29, 2021

Antengene announces first patient dosed in reach study of ATG-016 for the treatment of advanced solid tumors

December 28, 2021

Nivolumab plus ipilimumab benefits patients with asymptomatic melanoma brain metastases

December 28, 2021

Phase 2 study of selinexor for myelofibrosis progresses

December 27, 2021

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) approved in Japan for patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy

December 22, 2021

Selinexor approved in China for relapsed or refractory multiple myeloma

December 22, 2021

Scientists develop new immunotherapy for cancer based on transplant rejection mechanism

December 21, 2021

A new treatment may offer hope to patients with a type of bladder and urinary tract cancer

December 21, 2021

Nivolumab/cabozantinib improves survival in advanced renal cell carcinoma, even with bone metastasis

December 17, 2021

Merck receives positive EU CHMP opinion for KEYTRUDA® (pembrolizumab) as adjuvant therapy for certain patients with renal cell carcinoma following surgery

December 17, 2021

BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

December 16, 2021

STOMP trial supports selinexor in myeloma refractory to anti-CD38 monoclonal antibodies

December 16, 2021

Nivolumab and ipilimumab combination bests monotherapy in improving clinical outcomes in advanced melanoma

December 15, 2021

SIENDO study in endometrial cancer hits enrollment milestone

December 14, 2021

First patient dosed in the MIV-818 combination study

December 14, 2021

Antengene presents results of Phase 1b TOUCH Trial of selinexor for the treatment of T and NK-cell lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Selinexor with bortezomib and dexamethasone represent potential new option for high-risk myeloma

December 10, 2021

Darovasertib/crizotinib shows early efficacy in metastatic uveal melanoma

December 10, 2021

Frontline nivolumab/ipilimumab improves OS in advanced NSCLC, irrespective of mutational status

December 9, 2021

IO Biotech announces publication of phase 1/2 melanoma clinical trial results in Nature Medicine

December 9, 2021

Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody

December 8, 2021

PD-L1 cutoff for TNBC Keytruda benefit confirmed in KEYNOTE analyses, but questions linger

December 8, 2021

Which patients benefit most from immunotherapy? This tool can tell

December 7, 2021

IDEAYA reports clinical data from Phase 2 expansion dose of darovasertib and crizotinib synthetic lethal combination in heavily pre-treated metastatic uveal melanoma

December 6, 2021

Merus presents clinical data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

December 3, 2021

FDA approves Merck’s KEYTRUDA® (pembrolizumab) as adjuvant treatment for adult and pediatric (≥12 years of age) patients with Stage IIB or IIC melanoma following complete resection

December 2, 2021

Karyopharm completes patient recruitment in phase 3 SIENDO study of selinexor in patients with endometrial cancer

December 1, 2021

Dr. Luke on toxicities with targeted therapy vs immunotherapy in melanoma

December 1, 2021

BO-112 plus pembrolizumab improves ORR in advanced melanoma after progression on Anti–PD-1 therapy

November 29, 2021

European Commission Approves KEYTRUDA® Plus LENVIMA® as First-Line Treatment for adult patients with advanced renal cell carcinoma

November 22, 2021

FDA grants orphan drug designation to toripalimab for esophageal cancer

November 22, 2021

Use of first-line post-protocol immunotherapy appears low in kidney cell carcinoma clinical trials

November 21, 2021

Lenvatinib/pembrolizumab combo continues to show benefit in advanced endometrial cancer

November 19, 2021

Atezolizumab and nivolumab prolong overall survival compared with docetaxel in NSCLC

November 19, 2021

BioNTech’s skin cancer therapy wins FDA’s fast track designation

November 19, 2021

Scancell Holdings says phase II melanoma trial is underway after recruiting first patient

November 18, 2021

FDA approves Keytruda as adjuvant treatment for kidney cancer

November 18, 2021

Antengene announces IND approval in China for a phase I/II study of selinexor (ATG-010) in patients with non-Hodgkin lymphoma

November 18, 2021

FDA approves Mercks KEYTRUDA (pembrolizumab) as adjuvant therapy for certain patients with renal cell carcinoma (RCC) following surgery

November 17, 2021

OSE Immunotherapeutics Randomizes First Patient to Phase II Trial of Vaccine in Metastatic NSCLC

November 15, 2021

OSE Immunotherapeutics presented the first positive preclinical efficacy data on CLEC-1, a novel myeloid immune checkpoint target for cancer immunotherapy

November 15, 2021

First patient dosed with CyPep-1 in combination with KEYTRUDA® in Cytovation’s Ph I/IIa CICILIA clinical trial

November 13, 2021

Modified ipilimumab dosing in ipilimumab/nivolumab combo improves toxicity in advanced renal cell carcinoma

November 9, 2021

Rain Therapeutics plans phase 2 merkel cell carcinoma clinical trial (MANTRA-3) of milademetan

November 9, 2021

Coherus and Junshi Biosciences announced that the FDA accepted their Biological License Application for toripalimab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma

November 9, 2021

An international phase III study compared treatment outcomes between once-weekly selinexor plus bortezomib-dexamethasone, and twice-weekly bortezomib-dexamethasone alone in patients with multiple myeloma

November 9, 2021

Antengene to release preliminary results of selinexor for the treatment of peripheral t-cell lymphoma and nk/t-cell lymphoma at the 2021 ASH Annual Meeting

November 9, 2021

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

November 6, 2021

Early safety monitoring critical with lenvatinib/pembrolizumab in kidney cancer

November 3, 2021

Alpha Tau announces enrollment of first patient in combination trial of Alpha DaRT™ and pembrolizumab (Keytruda®) for the treatment of recurrent unresectable or metastatic squamous cell carcinoma of the head and neck

November 3, 2021

The FDA has accepted Memgen’s investigational new drug (IND) application for MEM-288, the company’s immunotherapy candidate for the treatment of multiple solid tumors

November 1, 2021

Antengene Corporation Limited announced that China’s National Medical Products Administration (NMPA) has approved an open-label Phase Ib dose-escalation study designed to assess the safety of ATG-008 (onatasertib) in combination with ATG-010 (selinexor) in patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL)

October 31, 2021

KEYTRUDA continued to improve Recurrence-Free Survival (RFS) compared to placebo as adjuvant therapy for patients with resected stage IIB or IIC melanoma at 2nd interim analysis of phase 3 KEYNOTE-716 trial

October 26, 2021

An expert in melanoma cancer treatment examines monitoring patients with melanoma using ctDNA.

October 25, 2021

FDA grants fast track designation to UV1 for advanced melanoma

October 25, 2021

FDA grants Fast Track Designation to nemvaleukin as treatment for ovarian cancer

October 25, 2021

Evaxion Biotech announces clinical collaboration to evaluate lead product candidate with KEYTRUDA® (pembrolizumab) in patients with melanoma

October 24, 2021

New study offers possible immunotherapy breakthrough for cancer

October 22, 2021

The European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC) whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5

October 22, 2021

The European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1

October 22, 2021

Neoadjuvant talimogene laherparepvec (T-VEC) followed by surgery significantly improved survival when compared with surgery alone in patients with advanced, resectable melanoma

October 21, 2021

Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer.

October 21, 2021

Antengene enters into a research collaboration and license option agreement with LegoChem Biosciences for new antibody-drug conjugate candidates

October 21, 2021

Ultimovacs receives dual FDA Fast Track Designation for UV1 in advanced malignant melanoma

October 20, 2021

GenFleet Therapeutics announced that the first patient with metastatic sigmoid adenocarcinoma has been dosed in a phase Ib/II trial of GFH018 in combination with toripalimab (anti-PD-1 monoclonal antibody) as part of global multi-center clinical research.

October 20, 2021

NeoTx Therapeutics, a clinical-stage immuno-oncology company, announced today that the first patient has been enrolled in the company’s phase 2a clinical trial of naptumomab estafenatox (NAP), its lead Tumor Targeted Superantigen (TTS) candidate, in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).

October 20, 2021

A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity

October 20, 2021

Merck KGaA taps CytoReason’s machine learning platform to profile immuno-oncology drug

October 19, 2021

Sarah P. Psutka, MD, discusses the efficacy of the combination of immune checkpoint inhibitor therapy plus tyrosine kinase inhibitor for the treatment of metastatic renal cell carcinoma

October 19, 2021

Defence Therapeutics scores again with new planned phase 1 trial evaluating its DC cancer vaccine candidate AccuVAC-D002 against melanoma

October 18, 2021

ctDNA reduction after tebentafusp predicts OS in uveal melanoma

October 11, 2021

Kintor Pharmaceutical Limited announces China NMPA approves clinical trial of ALK-1 and nivolumab combination therapy for the first-line treatment of advanced hepatocellular carcinoma

October 11, 2021

CatalYm presents updated tolerability and preliminary pharmacodynamics data from the first-in-human trial of CTL-002 in monotherapy and in combination with nivolumab

October 10, 2021

Combinations offer multiple treatment options in relapsed/refractory multiple myeloma

October 9, 2021

Axitinib plus anti-PD1 regimen is effective as first-line mucosal melanoma treatment

October 8, 2021

European Medicines Agency validates relatlimab + nivolumab application for advanced melanoma

October 8, 2021

First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural Mesothelioma

October 7, 2021

Novel peptide-drug conjugate enhances the efficacy of immunotherapy in preclinical cancer models

October 5, 2021

Tebentafusp Yields Long-Lasting Overall Survival Benefit in HLA-A*02:01+ Patients With Metastatic Uveal Melanoma

October 5, 2021

Guardant Health Begins Study of Reveal Liquid Biopsy Test to Predict Cancer Recurrence

October 1, 2021

UK Researchers Show Cytotoxic T-Cell Level Predicts Melanoma Immunotherapy Response

September 29, 2021

A subset of patients with metastatic uveal melanoma achieved promising responses after treatment with entinostat and pembrolizumab.

September 28, 2021

FDA Accepts Bristol Myers (BMY) supplemental biologics license applications for two combinations with Opdivo for esophageal squamous cell carcinoma

September 28, 2021

Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors

September 28, 2021

Keytruda Meets Endpoints in KEYNOTE Trial, Treatment of Hepatocellular Carcinoma

September 28, 2021

FDA grants priority review to Libtayo for advanced cervical cancer

September 27, 2021

Startup company Accession Therapeutics Ltd. hopes to develop the first oncolytic virus to be genetically engineered to exclusively infect cancer cells

September 25, 2021

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma

September 24, 2021

First patient with lung cancer treated in phase 2b tomivosertib trial

September 23, 2021

Eisai and Merck present first-time data from two studies evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) in seven different tumor types at ESMO Virtual Congress 2020

September 23, 2021

Alrizomadlin Granted FDA Fast Track Designation for Relapsed/Refractory Unresectable or Metastatic Melanoma

September 22, 2021

HUTCHMED has initiated a phase III study, SURTORI-01, to evaluate the efficacy and safety of surufatinib in combination with toripalimab for patients with advanced neuroendocrine carcinoma

September 20, 2021

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

September 19, 2021

Nivolumab/rucaparib combination induces clinically effective outcomes in patients with metastatic castration resistant prostate cancer who are HRD-positive in CheckMate 9KD trial

September 18, 2021

Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma [ESMO Congress 2021 Press Release]

September 16, 2021

Phase ½ investigator-sponsored trial launched to investigate evorpacept (ALX148) in combination with rituximab and lenalidomide for the treatment of patients with indolent and aggressive non-Hodgkin lymphoma

September 15, 2021

BioNTech wins FDA’s orphan drug status for melanoma candidate

September 15, 2021

Pulmocide’s lead drug candidate opelconazole (PC945) has been granted Orphan Drug, Fast Track, and Qualified Infectious Disease Product Designations for the treatment of invasive pulmonary aspergillosis by the FDA

September 14, 2021

Aprea to present phase 1/2 trial data of eprenetapopt-Keytruda combo to treat tumors

September 13, 2021

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update

September 13, 2021

Instil Bio to Begin Phase II Trial of TIL Therapy for Advanced Melanoma

September 12, 2021

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

September 12, 2021

Study shows durable remissions with the combination of pembrolizumab and chemotherapy in patients with EGFR/ALK-positive non-small cell lung cancer

September 9, 2021

Karyopharm Therapeutics Inc is recruiting patients for a study investigating selinexor in combination with pembrolizumab for the treatment of locally advanced or metastatic melanoma

September 8, 2021

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers

September 4, 2021

Keytruda receives full FDA approval for bladder cancer

September 2, 2021

Certain Genomic Pathways of Gut Microbiome Significantly Associated With Survival in Nivolumab-Treated Patients With Gastric/GEJ Cancer

September 1, 2021

BMS’ Opdivo greenlighted as first immunotherapy for first-line advanced gastric cancer in China

August 31, 2021

FDA Expands Indication of Keytruda for Bladder Cancer Subtype

August 27, 2021

Nivolumab and tumor-infiltrating lymphocyte regimen elicits activity in metastatic non-small cell lung cancer

August 26, 2021

Merck’s Keytruda (pembrolizumab) receives two new approvals in Japan

August 26, 2021

Cabozantinib plus nivolumab approved for unresectable or metastatic renal cell carcinoma in Japan

August 25, 2021

FDA grants priority review to tebentafusp for uveal melanoma treatment

August 25, 2021

FDA accepts biologics license application for tebentafusp in metastatic uveal melanoma

August 24, 2021

FDA approves adjuvant nivolumab for high-risk urothelial carcinoma following Checkmate-274 trial

August 24, 2021

Tebentafusp Gets Priority Review for Metastatic Uveal Melanoma

August 24, 2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

August 23, 2021

Foghorn Therapeutics announces first patient dosed in first-in-human clinical trial of FHD-609

August 23, 2021

Dr. Fakih on efficacy with regorafenib plus nivolumab in metastatic colorectal cancer

August 22, 2021

Researchers assess immune checkpoint inhibitor resistance in melanoma treatment

August 18, 2021

CheckMate-73L to explore ipilimumab and nivolumab combo in non-small cell lung cancer treatment

August 18, 2021

Werewolf collaborates with Merck on WTX-124 in combination with Keytruda

August 18, 2021

Inhibitor drug entinostat ‘primes’ the body to better respond to anti-cancer treatment with immunotherapy

August 17, 2021

Dysregulation of group 3 innate lymphoid cells (ILC3s) unleashes progression and immunotherapy resistance in colon cancer

August 17, 2021

European Medicines Agency validates Bristol Myers Squibb’s Applications for Opdivo + Yervoy and Opdivo + chemotherapy as first-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma

August 16, 2021

Phase II findings for nivolumab plus ipilimumab for metastatic castration resistant prostate cancer warrants further study

August 16, 2021

FDA Grants Fast Track Designation to IN10018 FAK inhibitor for treatment of platinum-resistant ovarian cancer

August 12, 2021

Merck and Eisai’s Keytruda-Lenvima combo rides strong data to FDA nod in kidney cancer

August 12, 2021

Adoptive cell therapy plus checkpoint inhibitors show promise in non-small cell lung cancer

August 11, 2021

CheckMate-73L to examine nivolumab/ipilimumab following nivolumab/chemoradiation in non-small cell lung cancer

August 10, 2021

Combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma (CHOPIN): Study protocol for a phase Ib/randomized phase II trial

August 10, 2021

FDA accepts two applications for expanded Keytruda use

August 9, 2021

Keytruda approved to treat high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment

August 5, 2021

Merck’s Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers

August 5, 2021

Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial

August 2, 2021

Ipilimumab plus nivolumab improves survival in melanoma with brain metastases

August 2, 2021

FDA grants Fast Track Designation to nemvaleukin alfa for mucosal melanoma

July 28, 2021

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

July 28, 2021

Study explores anti-PVRIG therapy plus nivolumab and anti-TIGIT therapy in advanced solid tumors

July 27, 2021

US FDA approves Merck’s Keytruda combo for early breast cancer treatment

July 26, 2021

Bristol Myers Squibb has voluntarily withdrawn liver cancer indication for Opdivo

July 26, 2021

FDA rejects Incyte’s retifanlimab, asking for more data to show clinical benefit

July 26, 2021

Bempegaldesleukin plus nivolumab elicits responses in treatment-naïve, advanced melanoma

July 23, 2021

Researchers have used patient-specific tumor organoid models to improve immunotherapy treatments for appendiceal cancer

July 23, 2021

FDA grants Orphan Drug Designation to alrizomadlin for stage IB-IV melanoma

July 22, 2021

Merck’s Keytruda and Eisai’s Lenvima win full approval for endometrial cancer

July 21, 2021

NOXXON Pharma enters second clinical collaboration with MSD to evaluate NOX-A12 in combination with Keytruda in upcoming phase 2 pancreatic cancer study

July 16, 2021

Bristol Myers Squibb’s Opdivo and Yervoy combo falls short in first-line squamous head and neck cancer

July 14, 2021

Regorafenib/nivolumab elicits better responses in patients without liver metastases in mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

July 14, 2021

BEMPEG plus nivolumab achieved “deep and durable” responses in previously untreated metastatic melanoma patients

July 13, 2021

Adjunctive nivolumab reduces risk of death and progression of gastric adenocarcinoma compared to chemotherapy alone

July 12, 2021

FDA approves Keytruda for the treatment of patients with locally advanced cutaneous squamous cell carcinoma

July 12, 2021

Combination of pembrolizumab and low-dose ipilimumab appeared to show significant antitumor activity among patients with advanced melanoma who previously failed immunotherapy

July 11, 2021

Cabozantinib fails to improve progression-free survival and results in more adverse effects in patients with renal cell carcinoma

July 9, 2021

Merk will withdraw Keytruda’s “dangling” indication for gastric cancer

July 8, 2021

Research group led by Herwig Moll identified a potential marker for the success of immunotherapy in lung cancer patients

July 7, 2021

OncoSec, Merck enter agreement for late-stage metastatic melanoma combo

July 7, 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer

June 30, 2021

Alpine Immune Sciences to collaborate with Merck on immune-oncology study to evaluate ALPN-202 in combination with Keytruda (pembrolizumab)

June 29, 2021

Merck’s Keytruda-Chemo combo wins European approval in esophagus cancer

June 28, 2021

In surprising flop, Exelixis’ Cabometyx combo with Roche’s Tecentriq fails to extend life in liver cancer

June 28, 2021

Galinpepimut-S plus nivolumab shows promising preliminary benefit in mesothelioma

June 25, 2021

Long-term benefits of nivolumab in pre-treated non-small cell lung cancer

June 24, 2021

Corbus Pharmaceuticals announces topline results from DETERMINE Phase 3 study of lenabasum for treatment of dermatomyositis

June 23, 2021

Rubius Therapeutics announces first patient dosed with RTX-240 in combination with Keytruda in ongoing Phase ½ clinical trial for the treatment of advanced solid tumors

June 23, 2021

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immune-oncology

June 22, 2021

MSD’s Keytruda proves effective for non-muscle-invasive bladder cancer

June 22, 2021

Merck says Keytruda extends survival in cervical cancer study

June 22, 2021

Targovax receives Fast Track designation for ONCOS-102 in melanoma

June 21, 2021

‘Suffocating’ cancer: a new headway in melanoma immunotherapy

June 21, 2021

Patients with advanced esophageal squamous cell carcinoma experience improved survival outcomes with addition of nivolumab to ipilimumab or chemotherapy

June 21, 2021

Nivolumab/ipilimumab triplet improves OS in advanced non-small cell lung cancer compared with chemotherapy alone

June 18, 2021

A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1

June 17, 2021

Merck’s KEYNOTE-564 data heralds early adjuvant Keytruda use in renal cancer

June 16, 2021

ODAC panel approves 4 of 6 anti-PD-1/PD-L1 drugs in accelerated approval program

June 15, 2021

Linnaeus Therapeutics announces expanded clinical collaboration with Merck to include multiple additional cohorts to evaluate LNS8801 in combination with Keytruda in patients with advanced cancer

June 14, 2021

Istari Oncology announces FDA granted fast track designation to PVSRIPO for the treatment of advanced melanoma

June 14, 2021

Exelixis announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate XL092 in combination with immune-oncology therapies in advanced solid tumors

June 11, 2021

Cetuximab after disease progression with immunotherapy in advanced skin cancer

June 10, 2021

Old antidepressants show promise as immuno-oncology treatments in melanoma and colon cancer

June 8, 2021

LARVOL launches platform to curate historical and active immuno-oncology clinical trial data in a digital dashboard

June 8, 2021

APG-115 plus pembrolizumab safe with preliminary efficacy in unresectable or metastatic melanoma or advanced solid tumors

June 7, 2021

Positive preliminary results from Delcath Systems’ FOCUS trial presented at the 2021 ASCO annual meeting

June 7, 2021

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

June 7, 2021

An overview of the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer

June 7, 2021

NeoImmune Tech trial data evaluating NT-I7 in combination with pembrolizumab as a treatment for advanced solid tumors presented at ASCO annual meeting

June 7, 2021

Melanoma outcomes are improved with nivolumab alone or with ipilimumab

June 7, 2021

Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

June 7, 2021

Alpine reports 61% ‘clinical benefit’ in early trial of CD28-targeted immune-oncology drug

June 6, 2021

Lifileucel continues to show durable responses in advanced melanoma

June 4, 2021

Surface Oncology to collaborate with Roche on immune-oncology study evaluating SRF388, targeting IL-27, as part of a novel combination in patients with advanced treatment-naïve hepatocellular carcinoma

June 4, 2021

Coherus and Junshi Biosciences announce toripalimab in combination with chemotherapy met primary progression free survival (PFS) endpoint as first line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)

June 4, 2021

Alkermes results presented at ASCO 2021 show a dwindling response rate in melanoma patients receiving nemva monotherapy

June 4, 2021

Nanobiotix’s radiotherapy enhancer for tumors also primes the immune system

June 4, 2021

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

June 4, 2021

Results presented at Asco show a dwindling response rate in melanoma patients receiving Alkermes’ nemvaleukin monotherapy

June 4, 2021

Iovance Biotherapeutics announces clinical data for lifileucel in combination with pembrolizumab in advanced melanoma at ASCO 2021 annual meeting

June 3, 2021

Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma

June 2, 2021

Researchers have identified a protein that helps tumors evade the immune system and, in certain types of cancers, is linked to poorer chance of survival

May 28, 2021

Combination therapy with nivolumab and relatimab prolongs progression-free survival in advanced melanoma

May 25, 2021

Xilio and Merck partner on anti-CTLA-4 antibody in combination with Keytruda in solid tumors

May 24, 2021

Scopus BioPharma Inc. announced the approval of an investigational new drug application by the FDA for CPG-STAT3siRNA, an immune-oncology RNA therapy for the treatment of multiple cancers

May 21, 2021

Japan’s Astellas Pharma and US biotech Seagen have announced updated results from clinical trials evaluating Padcev in combination with Keytruda in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy

May 21, 2021

Trial data shows durable, long-term survival with nivolumab, ipilimumab in patients with non-small cell lung cancer with PD-L1 expression

May 21, 2021

Bristol Myers wins positive opinion in Europe for Opdivo and Yervoy combo for colorectal cancer

May 21, 2021

Boehringer Ingelheim and OSE Immunotherapeutics unveiled preliminary data from a phase 1 trial of BI 7765063 at the 2021 ASCO annual meeting

May 21, 2021

Study shows cancer vaccine may boost immunotherapy effectiveness

May 21, 2021

RYBREVANT is the first fully-human, bispecific antibody approved in lung cancer

May 20, 2021

Researchers reported that targeted metabolic inhibitor stabilizes solid tumors in 60% of patients in phase 1 trial

May 20, 2021

Agenus presents new data on balstilimab and AGEN2373 in ASCO abstracts

May 20, 2021

Adjuvant Opdivo now approved by the FDA as a treatment for esophageal and gastroesophageal junction (GEJ) cancers

May 19, 2021

Merck details Keytruda and Herceptin combination win for stomach cancer at the annual ASCO meeting in 2021

May 19, 2021

New Bristol Myers immunotherapy combo better than Opdivo alone in melanoma study

May 19, 2021

Dual immunotherapy regimen targeting novel lymphocyte-activation gene 3 (LAG-3) immune checkpoint led to a significant progression-free survival (PFS) benefit in patients with advanced melanoma

May 19, 2021

Ascentage Pharma to announce updated results demonstrating clinical potential of alrizomadlin plus pembrolizumab in patients with advanced solid tumors that had failed immunotherapies at ASCO 2021

May 19, 2021

Biomarker panels evaluated by multiplex immunoassays with high analytical performance demonstrated potential complementary values in detection of uveal melanoma

May 19, 2021

6 ½ year outcomes for Opdivo in combination with Yervoy continue to demonstrate durable long-term survival benefits in patients with advanced melanoma

May 19, 2021

Nivolumab plus brentuximab vedotin shows efficacy for patients with mediastinal gray zone lymphoma

May 19, 2021

Merck’s LAG-3-targeting antibody, favezelimab, boosts Keytruda in metastatic colorectal cancer

May 17, 2021

BioMed X Institute and Merck extend collaboration to continue novel research in oncology and autoimmunity

May 14, 2021

Results from phase 3 KEYNOTE-522 trial showed that Keytruda met the dual-primary endpoint of event-free survival for treatment of high-risk early-stage triple-negative breast cancer patients

May 12, 2021

Exelixis’ Cabometyx scores backing from Ipsen in thyroid cancer with full data release set for ASCO

May 12, 2021

Bristol-Myers Squibb will present new data examining the combination of Opdivo plus Yervoy in various cancers in June’s American Society of Clinical Oncology (ASCO) Meeting

May 11, 2021

FDA approval summary of nivolumab plus ipilimumab for the treatments of patients with hepatocellular carcinoma previously treated with sorafenib

May 11, 2021

BostonGene and University of Pennsylvania’s Abramson Cancer Center to collaborate on immunotherapy studies

May 10, 2021

IMV Inc. announced that its lead compound, maveropepimut-S will be investigated in patients with hormone receptor positive/HER2-negative breast cancer

May 10, 2021

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients

May 7, 2021

Opdivo sBLA receives FDA acceptance and Priority Review for adjuvant treatment for patients with muscle-invasive urothelial carcinoma

May 7, 2021

New immunotherapy combinations are being explored in small cell lung cancer

May 6, 2021

Microneedles for cancer immunotherapy may lead to minimal invasiveness and side effects

May 6, 2021

Merck’s Keytruda has won FDA clearance to treat new patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma

May 6, 2021

Fusion Pharmaceuticals announces clinical collaboration with Merck to evaluate Fusion’s Targeted Alpha Therapy (TAT) in combination with Merck’s Keytruda in patients with solid tumors expressing IGF-1R

May 5, 2021

Alchemab to collaborate with AstraZeneca to use Alchemab’s Drug Discovery Platform for prostate cancer study

May 5, 2021

Checkmate Pharmaceuticals announces initiation of patient dosing in potential registration trial of Vidutolimod in patients with anti-PD-1 refractory advanced melanoma

May 5, 2021

Replimune provides a regulatory update for its registration-directed clinical trials evaluating RP! In combination with Libtayo

April 30, 2021

FDA panel denies support for maintaining Bristol’s Opdivo as liver cancer treatment

April 29, 2021

ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer

April 28, 2021

Biopharmaceuticals announces acceptance of PV-10 immunotherapy abstracts at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

April 28, 2021

Jemperli and Zynlonta have been approved by the FDA for advanced endometrial cancer and relapsed large B-cell lymphoma respectively

April 28, 2021

The virtual 2021 Great Debates and Updates in Women’s Oncology meeting presented a lively debate regarding immunotherapy for early triple-negative breast cancer (TNBC)

April 27, 2021

Alkermes initiates ARTISTRY-6 trial of nemvaleukin alfa monotherapy in patients with melanoma

April 26, 2021

Researchers have identified the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy

April 26, 2021

The FDA’s Oncologic Drugs Advisory Committee will be moving forward with a public review of 6 indications for immune checkpoint inhibitors granted under the agency’s accelerated approval process that later failed to reach thresholds for statistical significance in confirmatory clinical trials

April 23, 2021

ADC Therapeutics nabs its first approval as FDA offers a quick OK for its diffuse large B-cell lymphoma cancer treatment

April 23, 2021

GlaxoSmithKline immunotherapy Jemperli wins FDA approval for recurrent or advanced endometrial cancers with a specific type of genetic error that disrupts cells’ ability to repair DNA

April 23, 2021

Effects of Keytruda sustained after 3.5 years in high-risk stage 3 cutaneous melanoma

April 23, 2021

EU Panel recommends nivolumab/ipilimumab in frontline unresectable malignant pleural mesothelioma

April 22, 2021

Candel Therapeutics has announced it has completed enrollment for its phase I clinical trial in patients with newly diagnosed high-grade glioma to evaluate the safety and efficacy of CAN-2409 in combination with Opdivo

April 22, 2021

Adjuvant nivolumab improved disease-free survival in esophageal and gastroesophageal junction cancers with residual pathologic disease after resection

April 22, 2021

Immunotherapy combinations may hold promise in treatment of late-stage or recurrent endometrial cancer

April 22, 2021

Toripalimab plus chemotherapy as first-line treatment for advanced esophageal cancer reached primary endpoints in phase III clinical study

April 21, 2021

Opdivo has been granted an extended indication for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma

April 21, 2021

Istari Oncology announces publication of “A phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma” in the BMJ’s Journal for ImmunoTherapy of Cancer

April 16, 2021

IDEAYA reports clinical data from the ongoing phase 1/2 trial evaluating darovasertib monotherapy and binimetnib combination therapy in patients with solid tumors, including metastatic uveal melanoma and skin melanoma

April 15, 2021

AACR Forum Microbiome Pandemonium: Checkpoints and the Microbiome discusses growing evidence for the relationship between gut microbiota and the response of immune checkpoint inhibitors

April 14, 2021

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announced that three projects have been selected to study oral decitabine and cedazuridine

April 14, 2021

A new phase I study at the Memorial Sloan Kettering Cancer Center plans to assess the safety of RO7293583 immunotherapy in patients with metastatic melanoma that contains a protein called TYRP1

April 14, 2021

Panel discusses how combination therapies could create better, longer-lasting outcomes

April 13, 2021

The AACR’s Presidential Address, Fighting Melanoma with the Immune System, discussed how researchers are working to change the treatment paradigm for patients with melanoma through next-generation techniques that stimulate immune response and amplify antitumor activity

April 12, 2021

Forum considers when the right time is to utilize CAR-T therapies

April 11, 2021

First Clinical Trials Plenary features practice-changing data from phase III trials

April 10, 2021

Results from the AACR annual meeting show that patients with early-stage non-small cell lung cancer who took a combination of Opdivo and chemotherapy before surgery were nearly 14 times more likely to show no signs of cancer cells in their resected tissue compared with those who got chemo alone

April 10, 2021

Nivolumab plus paclitaxel shows clinical activity in advanced gastric cancer subgroup

April 10, 2021

Unselected autologous tumor infiltrating lymphocyte therapy shows early promise in patients with metastatic melanoma

April 10, 2021

Immunotherapy response prediction using tumor mutational burden may differ between men and women with melanoma

April 10, 2021

A liquid biopsy test to assess plasma cell-free DNA integrity could improve the accuracy of magnetic resonance imaging for predicting the achievement of complete response among patients with locally advanced breast cancer who had received neoadjuvant chemotherapy, according to results presented during Week 1 of the virtual AACR Annual Meeting 2021

April 10, 2021

Copanlisib-rituximab combination cuts lymphoma progression or death by nearly half in CHRONOS-3 trial

April 10, 2021

Neoadjuvant nivolumab plus chemotherapy increased pathological complete response rate in CheckMate-816 lung cancer trial

April 9, 2021

Case report describes myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis

April 9, 2021

The National Institute for Health and Care Excellence (NICE) has issued a preliminary no for NHS use of Bristol-Myers Squibb’s Opdivo/Yervoy combination for treating metastatic non-small-cell lung cancer

April 8, 2021

Merck announced that Keytruda has succeeded in a phase 3 trial in early kidney cancer

April 8, 2021

University of Texas MD Anderson Cancer Center and TriSalus Life Sciences announce collaboration on studies evaluating the administration of investigational SD-101 intravascularly via the FDA cleared Pressure-Enabled Drug Delivery (PEDD) technology across a range of liver and pancreatic solid tumors

April 8, 2021

Merck’s Keytruda demonstrated superior disease-free survival compared with placebo as adjuvant therapy in patients with renal cell carcinoma following surgery

April 7, 2021

PsiOxus Therapeutics updates agreement with Bristol Myers Squibb to advance their clinical stage immune-oncology collaboration to investigate the combination of NG-641 with Opdivo in several tumor types

April 1, 2021

Phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma finds talimogene laherparepvec upregulates immune-cell populations in non-injected lesions

March 30, 2021

Huyabio International announces Phase 3 global clinical trial collaboration with Bristol Myers Squibb for subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy

March 30, 2021

LATTICE radiotherapy plus immunotherapy shows promise in treating advanced bulky tumors

March 29, 2021

FDA issues a complete response letter (CRL) to Merck’s Keytruda for triple-negative breast cancer

March 26, 2021

Phase 2b VITAL study of gemogenovatucel-T immunotherapy demonstrates clinical benefit in homologous recombination proficient ovarian cancer

March 25, 2021

Bristol Myers Squibb announces RELATIVITY-047, a trial evaluating Anti-LAG-3 antibody relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma

March 25, 2021

Immuno-oncology treatments finding success with Combination Therapies

March 25, 2021

Chronic immune-related adverse events appeared more common than previously thought after adjuvant anti-PD-1 immunotherapy for stage III to stage IV melanoma according to study published in JAMA Oncology

March 24, 2021

Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

March 24, 2021

Adjuvant nivolumab improves disease-free survival in resected esophageal/gastroesophageal junction cancer according to phase III CheckMate 577 trial

March 22, 2021

Eucure Biopharma announces that its anti-CTLA-4 antibody (YH001) in combination with Junshi Biosciences’ TUOYI has demonstrated encouraging anti-tumor activity in Phase I trial

March 19, 2021

Noxopharm commences IONIC immune-oncology trial to test Veyonda and Opdivo combination against a range of tumor types

March 19, 2021

Merck and Eisai’s Keytruda-Lenvima Combo significantly improved progression-free survival in advanced endometrial cancer.

March 19, 2021

Phase II trial announced for regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma

March 18, 2021

Tilsotolimod plus Yervoy combo fails in anti-PD-1 refractory melanoma study

March 14, 2021

FDA evaluates status of 6 cancer drug indications that were granted accelerated approvals

March 12, 2021

AVEO Oncology announces collaboration with Bristol Myers Squibb to evaluate tivozanib and nivolumab combination for advanced relapsed or refractory renal cell carcinoma

March 11, 2021

Nouscom receives approval to begin phase 1b trials for novel personalized cancer immunotherapy

March 8, 2021

Roche withdraws Tecentriq for use treating people with bladder cancer whose disease has progressed after chemotherapy

March 5, 2021

Study observes survival improvement with Opdivo plus chemotherapy for the treatment of gastric and GEJ cancers

March 2, 2021

Researchers at Moffitt Cancer Center suggests that sequential administration of immunotherapy followed by targeted therapy prolongs anti-tumor responses in preclinical models

March 2, 2021

Merck & Co. voluntarily withdraws Keytruda’s indication in third-line small cell lung cancer

March 2, 2021

Phase III CONFIRM trial suggests effective use of Opdivo after chemotherapy for malignant pleural mesothelioma

March 2, 2021

Opdivo-Yervoy combination plus two cycles of platinum doublet chemotherapy shows significant improvement in survival of patients with advanced non-small cell lung cancer

March 1, 2021

Researchers at Columbia and MIT created a new technique called Perturb-CITE-sequencing to identify previously unknown resistance mechanisms to immune checkpoint inhibitors in melanoma patients

March 1, 2021

Researchers target p53 and RAS proteins in cancer immunotherapy using bispecific antibodies to curb tumor growth

February 26, 2021

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo in combination with Cabometyx for the first-line treatment of adults with renal cell carcinoma to be reviewed by the European Commission (EC)

February 25, 2021

Compugen reports encouraging results from their phase I study of COM701 monotherapy and in combination with Opdivo for various types of cancers

February 23, 2021

NeoImmuneTech receives U.S. FDA Investigational New Drug Clearance for Pilot Study of NT-17 (efineptakin alfa) for Progressive Multifocal Leukoencephalopathy

February 22, 2021

Cemiplimab approved as front-line therapy for advanced NSCLC

February 22, 2021

FDA grants Fast Track Designation to GEN-1 immunotherapy for patients with advanced stage III or IV ovarian cancer

February 22, 2021

AstraZeneca to withdraw Imfinzi in advanced bladder cancer treatment in the U.S. after confirmatory trial showed no improvement of Imfinzi checkpoint inhibitor use over chemotherapy

February 20, 2021

Australian researchers identify protein linked to better patient responses to checkpoint inhibitor immunotherapy

February 19, 2021

Immunocore’s novel bispecific protein, tebentafusp, granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA for uveal melanoma

February 18, 2021

New trial funding for Nektar Therapeutics’ bempegaldesleukin drug paired with Merck’s pembrolizumab for squamous cell carcinoma of the head and neck

February 18, 2021

Study findings by researchers at Memorial Sloan Kettering Cancer Center suggest that blocking cancer cells’ use of sugar could increase the effectiveness of immunotherapy

February 18, 2021

Phase III OlympiA trial investigating effect of PARP inhibitor Lynparza shows positive results in adjuvant setting for patients with early breast cancer

February 17, 2021

Immunitas Therapeutics uses single-cell RNA-sequencing to identify the NK gene KLRB1 as a candidate inhibitory receptor on NK and T cells with applicability as a target in cancer immunotherapy

February 17, 2021

Research suggests that cosmetic lasers may make immune checkpoint inhibitors more effective in treating cancers with low mutation numbers

February 17, 2021

Phase 2 of neoadjuvant tavokinogene teleplasmid plus nivolumab study doses first patient with operable, locally or regionally advanced melanoma before surgery

February 16, 2021

Immunotherapy-docetaxel combinations show promise in metastatic castration-resistant prostate cancer

February 16, 2021

Study findings indicate promising use of cord blood-derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma

February 15, 2021

Ludwig Cancer Research study identified novel mechanism for cancer immunotherapy using cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade to disable suppressive immune cells

February 15, 2021

Study from the University of Pittsburgh School of Medicine suggests MCT1 inhibition drugs may boost effects of cancer immunotherapy

February 15, 2021

FDA approves nivolumab-cabozantinib as first-line treatment of advanced renal cell carcinoma

February 11, 2021

Repertoire Immune Medicines and Dana-Farber Cancer Institute announce new research collaboration aimed to identify novel tumor antigen targets relevant to HPV+ head and neck tumors

February 10, 2021

Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

February 10, 2021

FDA ODAC votes against recommending Keytruda for breast cancer

February 10, 2021

Case study analyzes successful Nivolumab treatment for head and neck squamous cell carcinoma after allogeneic bone marrow transplantation

February 10, 2021

FDA approves the chimeric antigen receptor (CAR) T-cell therapy Breyanzi, lisocabtagene maraleucel, for large B-cell lymphomas

February 10, 2021

Targovax and Papyrus will run pre-clinical research to evaluate the feasibility of combining Oncolytic Virus (ONCOS) and Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML) tumor suppressor technology

February 10, 2021

Smectite promotes probiotic biofilm formation in gut for cancer immunotherapy

February 10, 2021

Study links greater survival benefits from immunotherapy in Black men to increased tumor plasma cells

February 8, 2021

Bristol Myers Squibb’s Opdivo reduces recurrence of muscle-invasive urothelial carcinoma

February 8, 2021

4D pharma announces new clinical trial using combined MRx0518, a Live Biotherapeutic product, and BAVENCIO monotherapies for locally advanced or metastatic urothelial carcinoma

February 8, 2021

Combination of Keytruda and Yervoy fails to prolong survival and delay disease progression of advanced non-small cell lung cancer

February 8, 2021

Joint radionuclide and immunotherapy approach for prostate cancer effective in mice

February 8, 2021

Multigene variant profiling assay to guide targeted immunotherapy selection in solid tumors

January 25, 2021

Korea-based microbiome technology company, Genome & Company, utilizes microbiome-based drugs in combination with Merck and Pfizer’s Bavencio in new U.S. clinical trials

January 13, 2021

FDA Grants Fast Track Designations in Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma

January 13, 2021

Istari wins orphan drug designation for melanoma therapy

January 11, 2021

Age May Not Impact Outcomes from Metastatic Renal Cell Carcinoma Treatment Despite Increased Toxicity in Older Patients

January 9, 2021

A Drug Indication Is Pulled From the Market: Now What?

January 8, 2021

Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

January 8, 2021

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

January 7, 2021

Eganelisib/Nivolumab Shows Encouraging Efficacy in Advanced, Metastatic Urothelial Carcinoma

January 4, 2021

Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer

January 2, 2021

Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome

December 23, 2020

The Society for Immunotherapy of Cancer (SITC) recommends actions for patients concerning SARS-CoV-2 vaccination and cancer immunotherapy

December 10, 2020

Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer Symposium

December 9, 2020

Stellar Results from Kintor’s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer

December 7, 2020

Researchers identify potential drug combination to treat uveal melanoma

December 7, 2020

FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer

December 7, 2020

Activity of Brentuximab Vedotin Plus Nivolumab Clinically Meaningful for Subset of Patients with HL

December 6, 2020

Personalized cancer vaccine shows promise in combination with pembrolizumab in HNSCC (presented at SITC)

December 4, 2020

Nivolumab demonstrates survival benefits in the adjuvant setting (indirect treatment comparison study presented at SITC)

December 3, 2020

Neoadjuvant Nivolumab Safe for Nonmetastatic High-Risk RCC

December 2, 2020

An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).

December 2, 2020

ONCOS-102 plus pembrolizumab induces responses in anti-PD1-refractory melanoma

November 30, 2020

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

November 13, 2020

Bempegaldesleukin plus nivolumab showed durable benefit in metastatic melanoma (SITC 2020)

November 13, 2020

Pembrolizumab approved in triple-negative breast cancer (TNBC)

November 8, 2020

Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic Uveal Melanoma

November 7, 2020

TMB Use as Immunotherapy Biomarker Fraught by Challenges, But Still Shows Potential

November 6, 2020

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

November 6, 2020

NICE rules nivolumab is not cost effective for use on NHS

November 3, 2020

Studies Find Connection Between Age and Melanoma Treatment Resistance

November 2, 2020

Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levels

October 31, 2020

Cabozantinib Plus Nivolumab Improves Efficacy Over Sunitinib in mRCC

October 19, 2020

How Do Melanoma Comorbidities Affect Patient Treatment Preferences?

September 21, 2020

ESMO 2020 Virtual Conference: Immunomedics wows ESMO with breast cancer data reveal

September 21, 2020

ESMO 2020 Virtual Conference: Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

September 21, 2020

ESMO 2020 Virtual Conference: QUANTITATIVE SUMMARY OF QOL DATA CONFIRMS IMMUNE CHECKPOINT INHIBITOR THERAPY IS GENERALLY WELL-TOLERATED

September 21, 2020

ESMO Virtual Conference 2020: IMMUNOTHERAPY IS BENEFICIAL IN GASTRIC AND ESOPHAGEAL CANCERS, STUDIES SHOW

September 20, 2020

ESMO 2020 Virtual Conference: PEMBROLIZUMAB DELIVERS CLINICAL BENEFIT IN SELECTED HISTOTYPES OF RARE SARCOMA

September 19, 2020

ESMO 2020 Virtual Conference: Results for Sacituzumab govitecan-hziy in breast and bladder support this antibody-drug conjugate

September 19, 2020

ESMO Virtual Conference 2020: Results from IO Therapy for Triple Negative Breast Cancer

September 19, 2020

ESMO Virtual Conference 2020: Nivolumab and cabozantinib effective in first-line treatment for metastatic kidney cancer

September 18, 2020

Durvalumab demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years

September 18, 2020

2020 ESMO Virtual Congress 2020: Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO

September 17, 2020

ESMO Virtual Congress 2020: Nivolumab + Ipilimumab vs. Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma in CheckMate 214: 4-Year Follow-up and Subgroup Analysis of Patients without Nephrectomy

September 14, 2020

Adjuvant Opdivo shows promise in Esophageal-GEJ Cancer Patients

September 12, 2020

Higher Microbial Diversity May Be Associated with Better Outcomes in Patients with RCC

September 10, 2020

Validation of AI tools for cancer immunotherapy may be a step closer

September 10, 2020

Nivolumab/ipilimumab dual immune-checkpoint blockade active in mCRPC

September 8, 2020

Nivolumab/Ipilimumab Established as New Standard in Frontline sRCC

August 20, 2020

Merck’s oral cancer drug targeting STING boosts PD-1 immune blockade in mice

August 20, 2020

Immunotherapy Combo Shows Positive Results for Mesothelioma

August 19, 2020

Young Female Patients Have Low Response Rates to Immunotherapy

August 19, 2020

Pembrolizumab regimen extends survival in advanced esophageal cancer

August 19, 2020

Greater Diversity in Gut Microbiome Associated with Better Cancer Immunotherapy Outcomes

August 18, 2020

New App Helps Clinicians Manage Checkpoint Inhibitor AEs

August 15, 2020

CAR-NK Cell Immunotherapy Shows Promise

July 30, 2020

FDA Approves Atezolizumab Targeted Therapy Triple Combo for BRAF V600 Unresectable or Metastatic Melanoma

June 29, 2020

Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer

June 29, 2020

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

June 27, 2020

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

June 25, 2020

Noadjuvant Melanoma Combo Improves RFS in Macroscopic Melanoma

June 24, 2020

FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma

June 9, 2020

Dramatic Drop in Skin Cancer Referrals During COVID-19 Crisis

June 8, 2020

New findings with immunotherapy in the adjuvant setting for Merkel Cell Carcinoma

June 8, 2020

Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study

June 8, 2020

Personalized treatment strategies in melanoma could reduce toxicity burden from immunotherapy without compromising benefits

June 3, 2020

Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1

May 28, 2020

Immunotherapy Avelumab Shows Potential in Rare Gynecologic Cancer Resistant to Chemotherapy

May 28, 2020

Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With Specific DNA Mutations

May 18, 2020

FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup

April 28, 2020

FDA Approves Every-6-Week Pembrolizumab Dosage

April 27, 2020

Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six Weeks (Q6W) Comparable to Approved 200 mg Every Three Weeks (Q3W) Regimen

April 27, 2020

Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma

April 10, 2020

Checkpoint Combo Runs the Table in Early CRC

March 31, 2020

Skin Cancer Education & Research Foundation Launches New Website – A New Resource for the Fight Against Skin Caner.

March 25, 2020

Seattle Cancer Care Alliance, at the epicenter of the US epidemic, provides insights for cancer care during the evolving the COVID-19 crisis.

February 12, 2020

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)

February 12, 2020

Dealing with Coronavirus (COVID-19): Recommendations from the CDC

February 11, 2020

Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye

February 11, 2020

Jounce Using New Predictive Biomarker to Select Patients for Upcoming Phase II Immunotherapy Trial

February 10, 2020

Geneos to Test GNOS-PV02 Cancer Vaccine in Triple Combo Trial for Advanced Liver Cancer

February 3, 2020

First Patient Dosed in Proof-of-concept Study of CS1001 Plus Stivarga for Advanced Solid Tumors

January 26, 2020

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

January 23, 2020

FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancers

January 15, 2020

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer

January 13, 2020

Influenza Vaccines Triggers Immune System Response in Tumors

January 12, 2020

Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients

January 11, 2020

Early-Stage Leukemia Vaccine Study Reports 80% Survival Rate

January 8, 2020

FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

January 8, 2020

U.S. cancer death rate sees largest yearly drop

January 3, 2020

Tislelizumab-Chemo Combo Induces Durable Responses in Patients with Stomach, Esophagus Cancers, Trial Data Show

December 13, 2019

Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

December 9, 2019

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma

December 9, 2019

Nivolumab shows promise in ‘wide variety’ of mismatch repair-deficient cancers

December 8, 2019

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

December 8, 2019

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)

December 8, 2019

Hyperprogression Halts Study of Nivolumab in Peripheral T-Cell Lymphomas

December 8, 2019

Speeding Access To New And Innovative Cancer Treatments

November 20, 2019

Opdivo/Yervoy combo for melanoma fails in key patient population

November 1, 2019

5-year survival data positive for nivolumab-based regimens in advanced melanoma

November 1, 2019

STING pathway may be key to tumor cell recognition by immune cells

October 29, 2019

ASDS Steering committee develops evidence-based consensus on cSCC staging, workup, treatment

October 28, 2019

Managing Hematological Immune-Related Adverse Events With Immune Checkpoint Inhibitors

October 28, 2019

Nivolumab improves survival in non-small cell lung carcinoma, study results suggest

October 28, 2019

IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer

October 28, 2019

Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds

September 27, 2019

Maeton’s OT101 Gets Rare Pediatric Disease Designation for Childhood Brain Tumor

September 27, 2019

Systemic immune response in squamous cell carcinoma of the head and neck: A comparative concordance index analysis

September 26, 2019

Tasmanian devil research could help tackle immunotherapy resistance

September 26, 2019

Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated

September 26, 2019

IL-10-based therapy shows promise when used in combination with anti-PD1 agents in lung and RCC

September 26, 2019

Metabolic Imbalance Associated with Resistance to Checkpoint Inhibitor Nivolumab

September 26, 2019

Boost in Survival Rates for Younger Patients With Melanoma Attributed to Immunotherapy Agents

September 4, 2019

Nivolumab more effective versus investigator’s choice in younger vs older patients with recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)

September 4, 2019

TGF-Beta may be a predictive biomarker for response to pembrolizumab in HCC

September 3, 2019

Pooled Analysis Shows Triple OS with Nivolumab in Advanced NSCLC

August 30, 2019

Myasthenia gravis induced by avelumab

August 22, 2019

Anti-TNF therapy given concurrently with ICI therapy may be beneficial in patients with GI irAEs

August 16, 2019

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled, phase 3 trial

August 16, 2019

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma

August 16, 2019

ADXS-NEO Provoked Strong Immune Response in Advanced Cancer Patient, Early Trial Data Show

August 14, 2019

ICIs may trigger rare form of bullous pemphigoid

July 27, 2019

Wealth of Immunotherapy Combinations Places Emphasis on Biomarkers for NSCLC

July 26, 2019

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

July 25, 2019

Update on Frontline Nivolumab/Ipilimumab Combo Demonstrates Positive OS Results in PD-L1+ NSCLC

July 19, 2019

Prophylactic anti-TNF Therapy Improves Safety of Immunotherapies, Mouse Study Says

July 12, 2019

Libtayo Approved in Europe to Treat Metastatic or Advanced Cutaneous Squamous Cell Carcinoma

July 10, 2019

Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors

June 19, 2019

Implementation of a Multidisciplinary Approach for Managing Immunotherapy-Related Toxicities

June 18, 2019

Colorectal Cancer Vaccine Candidate Induces Potent Immune Responses, Interim Trial Results Show

June 18, 2019

Phase 1 Study Demonstrates Safety of Pembrolizumab in Patients With HIV and Advanced Cancer

June 18, 2019

Keytruda approved for metastatic small cell lung cancer that has progressed after previous treatment

June 4, 2019

Alternate Doses of Ipilimumab Show Similar Results in Advanced Melanoma

May 27, 2019

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

May 22, 2019

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

May 17, 2019

Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma

May 16, 2019

First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals

May 16, 2019

Immunotherapy response differs by EFGR mutation subtype

May 16, 2019

FDA approves Bavencio with Inlyta for patients with advanced renal cell carcinoma

May 14, 2019

Adopted cell transfer therapy being studied in sarcoma

May 2, 2019

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

May 1, 2019

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

April 30, 2019

Keytruda-Inlyta combo approved by FDA for untreated advanced kidney cancer

April 22, 2019

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)

April 16, 2019

Clinical Trial in Ireland Investigates Cellular Immunotherapy as Treatment for Two Autoimmune Liver Diseases

April 15, 2019

The Gut Microbiome & Cancer Immunotherapy

April 15, 2019

Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma

April 15, 2019

Cancers ‘change spots’ to avoid immunotherapy

April 12, 2019

TKI-Immunotherapy Combinations Push the Envelope in Frontline RCC

April 11, 2019

First Off-the-Shelf Immunotherapy Clinical Trial Launched

April 11, 2019

FDA Expands Keytruda Indication for First-Line Treatment of Non-Small Cell Lung Cancer

April 10, 2019

Comorbidities Result in Fewer Patients in Clinical Trials

April 10, 2019

Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories

April 10, 2019

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

April 9, 2019

Incysus Therapeutics gets FDA approval for brain cancer treatment trial

April 9, 2019

SWOG cancer research network study opens window into immune microenviroment

April 9, 2019

The changing landscape of diagnostic biomarkers: Exploring the one-biomarker-per-drug paradigm in oncology

April 8, 2019

Cancer ‘vaccine’ shows promise in human trial of lymphoma patients

April 8, 2019

Clinical Trial Investigates Orbsen Therapeutics’ ORBCEL-C™ Immunotherapy as Treatment for Two Autoimmune Liver Diseases

April 7, 2019

Researchers Develop “Swiss Army Knife” Immunotherapy to “Kick and Kill” HIV

April 5, 2019

Fecal transplants could help patients on cancer immunotherapy drugs

April 2, 2019

Gut microbes can spur immune system to attack cancer

April 1, 2019

UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells

April 1, 2019

Despite research boom, few immunotherapy studies targeting pancreatic cancer

April 1, 2019

How immune cells help tumors escape body’s defenses

March 31, 2019

AACR 2019 Research Roundup: Pancreatic Cancer Immunotherapy, Prostate Cancer Drug Resistance, Insight into Inherited Cancer Mutations

March 30, 2019

ETH researchers take major step towards personalized cancer immunotherapy

March 29, 2019

Combining DNA Damage Response Inhibitors with Immunotherapy Boosts SCLC Clearance, Mouse Study Shows

March 29, 2019

Immunotherapy for Pre-Cancerous Lesions May Reduce Skin Cancer Risk Over Time

March 28, 2019

Harnessing T-cell “stemness” could enhance cancer immunotherapy

March 28, 2019

Better Muscle Mass Linked to Improved Immunotherapy Response

March 28, 2019

New study confirms EpCAM as promising target for cancer immunotherapy

March 24, 2019

Bladder Cancer Guidelines Showcase Advent of Immunotherapy

March 22, 2019

FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC

March 21, 2019

Immunotherapies for Staphylococcus aureus

March 21, 2019

Imugene gains guidance for KEY-Vaxx Immunotherapy development

March 21, 2019

New U.K. Partnership Aims To Improve Access Immunotherapy For Cancer Patients

March 21, 2019

OHSU Knight Cancer Institute Throws Out Old System Of Clinical Trials

March 20, 2019

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

March 18, 2019

Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy

March 15, 2019

TC BioPharm, Trinity College Dublin Pair to Develop Cancer-fighting Cell Therapy

March 13, 2019

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13, 2019

Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals

March 12, 2019

Harness the immune system to fight colon cancer

March 11, 2019

FDA Approves Tecentriq-Abraxane Combo as First Immunotherapy Regimen for Breast Cancer

March 11, 2019

Unique Immunotherapy Combinations Provide an Optimistic Outlook in Early Urothelial Carcinoma Trials

March 8, 2019

Precision drugs could unmask cancers to immune system and boost effects of immunotherapy

March 8, 2019

FDA approves 1st immunotherapy drug to treat breast cancer

March 8, 2019

Immunotherapy in Bladder Cancer

March 8, 2019

More News! Targeting tuberculosis, light-activated drugs, cancer immunotherapies and more

March 8, 2019

Recognizing Endometrial Tumor Immune Features Is Key to Treatment Success